Breast cancer+2
Not yet recruitingGedatolisib with drug combination versus standard therapy as first‑line treatment for patients with advanced HR‑positive HER2‑negative breast cancer
Gedatolisib with drug combination versus standard therapy as first‑line treatment for patients with advanced HR‑positive HER2‑negative breast cancer
- Disease:Breast cancerHormone receptor positive breast cancer+1
- Substances:DexamethasoneFulvestrant+4
Poland- Participants:18–64 years · 65+ years
- Substances:Dexamethasone
- Sponsor:Celcuity Inc.



